Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OM336 desensitization trial for highly sensitized kidney transplant candidates
2025-523222-40-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Jul 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gamgertamig in end-stage kidney disease (ESKD), sponsored by Medical University of Vienna. Planned start Jul 2026; status: authorised.
02
Drugs
gamgertamig
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2025-523222-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523222-40-00.